Karleung Siu, MD
Hematology · Teaneck, NJNPI 1649417437
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), travel and lodging and other — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Sirtex Medical Inc at 39.1% of the total.
Across 82 payments — averaging $30.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sirtex Medical Inc$972
- Novartis$287
- Merck$163
- AstraZeneca$130
- Seagen Inc.$117
- Pfizer$116
- plus $700 from 17 others
Across 10 payments — averaging $4251.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$20K
- ADC Therapeutics America, Inc.$15K
- Genentech, Inc.$7K
What the payments were for
- Travel & lodging$74630%
- Food & beverage$1,35855%
- Education$1827%
- Other$1998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sirtex Medical Inc | 8 | $972 |
| Novartis | 7 | $287 |
| Merck | 9 | $163 |
| AstraZeneca | 9 | $130 |
| Seagen Inc. | 8 | $117 |
| Pfizer | 7 | $116 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $99 |
| Incyte Corporation | 2 | $98 |
| Johnson & Johnson(2 entities) | 5 | $82 |
| Bayer | 4 | $75 |
| E.r. Squibb & Sons, L.L.C. | 4 | $53 |
| Eisai Inc. | 3 | $41 |
| Lilly USA, LLC | 2 | $40 |
| EMD Serono, Inc. | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Sanofi | 2 | $29 |
| Taiho Oncology, Inc. | 1 | $23 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Beone Medicines USA, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Tesaro, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,486 in reported general payments places this provider in the 60th percentile of 43 hematology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 52 | $892,093 |
| BrukinsaZanubrutinib | 34 | $464,607 |
| RevlimidLenalidomide | 13 | $298,508 |
| PromactaEltrombopag Olamine | 14 | $272,215 |
| CalquenceAcalabrutinib Maleate | 14 | $206,256 |
| ZarxioFilgrastim-Sndz | 12 | $126,880 |
| XermeloTelotristat Etiprate | 11 | $106,227 |
| EliquisApixaban | 98 | $84,418 |
| PegasysPeginterferon Alfa-2a | 19 | $81,439 |
| XareltoRivaroxaban | 36 | $39,241 |
| Enoxaparin Sodium | 11 | $8,437 |
| Anastrozole | 151 | $3,289 |
| Exemestane | 14 | $2,106 |
| Lamivudine HbvLamivudine | 12 | $1,923 |
| Oxycodone Hcl | 43 | $1,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $98 | $892,09352 claims |
| NovartisPromacta | $287 | $272,21514 claims |
| AstraZenecaCalquence | $130 | $206,25614 claims |
| PfizerEliquis | $116 | $84,41898 claims |
| Johnson & JohnsonXarelto | $82 | $39,24136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 43 hematology providers in New Jersey.
Other hematology in Teaneck
- Ahmed GalalMorristown$1.7M
- Mansi ShahNew Brunswick$131K
- Fermina MazzellaNewark$49K
- Muhammad AbbasiMountain Lakes$22K
- Robert TassanWestwood$21K
- Marcus CarrNorth Brunswick$19K
- Jason LevitzMountain Lakes$19K
- Christopher TullyMountain Lakes$17K
- Claire PhilippNew Brunswick$17K
- Tiffany PompaMarmora$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.